Edwards Lifesciences Corporation (NYSE:EW) Shares Bought by Cerity Partners LLC

Cerity Partners LLC grew its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 67.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 212,923 shares of the medical research company's stock after acquiring an additional 86,089 shares during the quarter. Cerity Partners LLC's holdings in Edwards Lifesciences were worth $15,433,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the company. Crowley Wealth Management Inc. bought a new position in Edwards Lifesciences during the fourth quarter worth about $26,000. Vega Investment Solutions bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $27,000. Millstone Evans Group LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $29,000. Global X Japan Co. Ltd. increased its holdings in shares of Edwards Lifesciences by 116.1% during the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after acquiring an additional 216 shares during the last quarter. Finally, Tradewinds Capital Management LLC increased its holdings in shares of Edwards Lifesciences by 102.5% during the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock worth $29,000 after acquiring an additional 205 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 2,570 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $77.40, for a total transaction of $198,918.00. Following the transaction, the vice president directly owned 50,356 shares in the company, valued at $3,897,554.40. The trade was a 4.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $75.23, for a total value of $673,308.50. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at $15,565,087. This represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,848 shares of company stock worth $2,314,488 over the last 90 days. Insiders own 0.34% of the company's stock.

Edwards Lifesciences Trading Down 1.5%

Shares of Edwards Lifesciences stock traded down $1.14 on Tuesday, hitting $77.14. 952,322 shares of the company traded hands, compared to its average volume of 5,245,694. The stock's 50 day moving average price is $76.36 and its 200-day moving average price is $73.37. The company has a current ratio of 4.45, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52 week low of $58.93 and a 52 week high of $91.49. The company has a market cap of $45.25 billion, a PE ratio of 11.00, a PEG ratio of 3.92 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 16.62% and a net margin of 75.48%. The firm had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same quarter in the prior year, the business posted $0.66 EPS. The business's revenue for the quarter was up 6.2% compared to the same quarter last year. Equities research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on EW. Morgan Stanley increased their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the stock an "equal weight" rating in a report on Tuesday. Robert W. Baird increased their price target on Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research note on Thursday, April 24th. Wall Street Zen cut Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Friday, May 16th. Truist Financial reduced their price objective on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Finally, Dbs Bank upgraded Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of "Hold" and a consensus price target of $80.70.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.